Genmab — December 2017

[E_L]

haha

[Mcjean]

But didnt expect you to make a slidesshow or posters.........very impressive indeed

[Mcjean]

Joaquin could leran a little from JDW, he sound not very optimistic but maybe i overkill the sentence and the way he express himself.

[E_L]

J&J’s Darzalex set to shake up frontline treatment of multiple myeloma https://www.pharmaceutical-technology.com/comment/jjs-darzalex-set-shake-frontline-treatment-multiple-myeloma/ , addressing 1 of the questions i would hope to get a bit more clarity on during ASH; can D-VMP compete with VRD in the US? would be a nice positive short term

[mobbyduck1]

I am still afraid, that we will struggle, until we have a teach deal. 18 months ago, we had a large queue at the cashier??? and only 2 months ago, we had another promise, that we will see a tech deal in 2017, well there is very little time left. . It means so much not to disappoint the market, and we have done it over and over again, regarding these tech deals

[E_L]

Hang in there mobby; it is almost weekend, 2 whole days without falling prices!

[E_L]

Dr. Usmani has chosen Abstract 3110 as one of his favorites. This abstract is the use of Kyprolis, Revlimid, dex and daratumumab for newly diagnosed myeloma patients. https://www.myelomacrowd.org/ash-2017-myeloma-experts-favorite-ash-abstract-pick-dr-saad-usmani/

[kbsv]

the 12-month progression free survival rate was 95%

[kbsv]

Nice link once again, thanks EL

[mobbyduck1]

E:L I am hanging in there m8, with the Pedal fully down, but I still se these tech deals as the biggest problem, there is nothing wrong with the Case, everything else is these usual bumps. It would have been lot easier not to mention anything about these deals, then there would not be any problems

[rex_pacis]

I agree, if JvdW doesn't deliver what he promised, market will show a negative reaction

[OHW]

Det en del af marked ser, er et lille firma på en obskurt lille børs i en afkrog af verden, hvis umiddelbare fremtid styres af JJ med hård hånd og med en storskrydende upålidelig CEO

[Raffles]

@EL 08:55, Joaquin Duato says “......and we still will continue to see Darzalex in combination with there therapies being used in clinical practice”. Is he actually saying that Darzalex in future will be used in combination with potential new therapies like BCMA, CAR—T etc.???

[Bulder]

D-KRd har udviklet sig siden ASCO: Fra 5% CR til 43% sCR!. Dog 6 mdr PFS fra 100% til 12 mdr PFS 95%. Forventeligt. https://meetinglibrary.asco.org/record/144701/abstract

[Bulder]

Sådan læser jeg det også Raffles. Det kommer jo i direkte forlængelse af snak om de nye terapier, som uvægerligt vil komme.

[Joakim_Von_And]

Hold nu op med at kritisere JvdW, han gør det strålende med de betingelser han har ...

[Raffles]

Tak Bulder. Hvis det er tilfældet skal vi jo ikke “frygte” CAR—T m.v., men byde det velkommen da det kan udbygge salget dog med reduceret vedligeholdelsesbehandlinger???

[Bulder]

Eller måske netop car-t som induktion og dara som vedligeholdelse?

[Bulder]

Men vi mangler long term data på car-t for at se om der er behov for vedligeholdelse.

[E_L]

He is not referring to CAR-T though is he?
he refers to bispecifics. BCMA is not necessarily CAR-T